A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
07/09/2022at 14:56

Zealand Pharma intensifies partner hunt for other drug candidates

On Wednesday, the Danish biotech firm struck a deal with Novo Nordisk, giving the giant the commercial rights to its rescue pen, and it is now looking for similar agreements with other parties, says CEO Adam Steensberg.
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

Zealand Pharma’s newly inked deal with Novo Nordisk is just one of many that the Danish biotech company intends to sign over the next few years. In March, Zealand Pharma changed its strategy to focus on research and development, choosing to let other companies take charge of future commercialization efforts.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma

    Zealand CEO: Novo Nordisk is "the perfect partner" to market rescue pen

    For subscribers

  • Novo Nordisk has purchased the rights to Zealand Pharma's rescue pen, Zegalogue | Photo: Novo Nordisk / PR

    Analyst: Zegalogue launch should be "plug and play" for Novo Nordisk

    For subscribers

  • Photo: Novo Nordisk / PR

    Novo Nordisk licenses hypoglycemia drug from Zealand Pharma

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

In just a few years, Phillips-Medisize has doubled its staffing, and is now expanding its production facility in Danish town Struer to keep up with demand.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Steven Russell, incoming chief medical officer at Beta Bionics | Foto: Beta Bionics/PR
Pharma & biotech

Bionic pancreas system nears commercial launch

The biotech company, a partner of Novo Nordisk and Zealand Pharma, among others, hires a chief medical officer ahead of a commercial launch of the bionic pancreas system. 

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Head of International Sales

  • Lead Data Architect

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

  • Application Manager

See all jobs

Jobs

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Head of International Sales

  • Lead Data Architect

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge